Acadia Pharmaceuticals ACAD Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's restricted cash?
- Acadia Pharmaceuticals (ACAD) reported restricted cash of $7.85M in Q1 2026.
- How has Acadia Pharmaceuticals's restricted cash changed year-over-year?
- Acadia Pharmaceuticals's restricted cash decreased by 10.5% year-over-year, from $8.77M to $7.85M.
- What is the long-term trend for Acadia Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's restricted cash has grown at a 6.3% compound annual growth rate (CAGR), from $5.77M to $7.85M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.